Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Nutriband Inc. (NASDAQ: NTRB) Lands On The Krypton Street Watchlist For This Morning—Friday, September 25, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At (NTRB) While It’s Still Early… September 25, 2026 Dear Reader, We’re starting the day with Nutriband Inc. (NASDAQ: NTRB) near the top of our screen. A small public float, an approaching registration study, and recent share momentum are giving us several reasons to stay focused. A 205% move in less than seven weeks… That's what Nutriband Inc. (NASDAQ: NTRB) put together between early August and September 21, according to Barchart — running from around $2.80 to $8.55. On a name with fewer than 6M shares in the public float, that kind of momentum speaks for itself. But the more interesting question isn't what already happened… It's what's ahead. Nutriband Inc. (NASDAQ: NTRB) is a pharmaceutical company developing what could become the first abuse-deterrent fen-tan-yl patch available in the United States — and we're now entering the stretch where a registration trial, a warrant expiration, and a full commercialization roadmap all converge at once. There is not a single abuse-deterrent fen-tan-yl patch on the U.S. market today. Not one. Every generic fen-tan-yl patch currently available can be tampered with, misused, or accidentally exposed to someone who should never come in contact with the dr-ug at all. Think about that for a moment. A $1.2B market for transdermal fen-tan-yl patches, and not a single product on the shelf has been engineered to deter abuse. That's the problem Nutriband Inc. (NASDAQ: NTRB) was built to solve. And we think the timing of what's coming together right now is worth a very close look. Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist this morning—Friday, September 25, 2026.
According to Yahoo Finance, (NASDAQ: NTRB) has a float less than 6M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. Why AVERSA™ Deserves Your Attention
The opi-oid crisis isn't a headline anymore… It's a permanent feature of American life. According to the White House, illicit opi-oids — primarily fen-tan-yl — now cost Americans an estimated 9.7 percent of GDP annually. 
That's a staggering number — and it has only grown in recent years. Ninety-three percent of opi-oid-related deaths involve synthetic opi-oids like fen-tan-yl. Forty-one percent of the total cost comes from deaths alone, with another 49 percent reflecting lost quality of life for those living with opi-oid use disorder. The FDA and DEA responded to this crisis by restricting prescribers, manufacturers, and pharmacies — which made fen-tan-yl patches harder to access for the chronic pain patients who genuinely need them. The unintended consequence was significant — and well documented. It created a vacuum that illicit fen-tan-yl rushed in to fill, making the addiction crisis worse rather than better. What patients needed was a way to receive safe, controlled transdermal fen-tan-yl without the abuse risks that triggered the crackdown. That's exactly what the AVERSA™ technology inside (NTRB) is designed to deliver. The technology incorporates aversive agents directly into the patch, preventing removal of the fen-tan-yl — meaning the dr-ug can only reach the patient through controlled absorption, as intended. When used correctly, fen-tan-yl patches provide meaningful relief for chronic pain. The problem has always been what happens when they're not used correctly — and AVERSA addresses that at the physical layer, through the chemistry of the patch itself. This is not a software solution or a labeling change. It's an engineering answer to a medical problem — built directly into the product. The current U.S. market for generic transdermal fen-tan-yl patches is estimated at over $1.2B, and according to the company's own analysis, AVERSA fen-tan-yl has the potential to reach peak annual U.S. revenues of $80M to $200M. The technology is protected by patents granted across 46 countries, including the United States, Europe, Japan, Korea, China, Canada, Mexico, and Australia. And there's a regulatory angle worth flagging here… The FDA has historically moved to require abuse-deterrent technology across all formulations in a dr-ug category once the first abuse-deterrent version becomes available. If that precedent holds, the addressable market for (NTRB) could expand well beyond what initial projections suggest. The Timeline Is Tightening
This is the part where things start to compress… The FDA filing pathway for AVERSA fen-tan-yl requires only a single clinical trial — providing data to show that fen-tan-yl abusers prefer generic patches over the abuse-deterrent AVERSA technology. According to Noble Capital Markets, manufacturing of clinical supplies is progressing, with the trial expected to begin around late Fall 2026. This is a short trial design with a relatively small number of patients — it's the 505(b)(2) pathway, which means the company can reference existing approved products rather than starting from scratch. Noble's valuation framework suggests that if the NDA filing proceeds on schedule, a standard 10-month review could put FDA approval within reach by late 2026 or into 2027. Noble Capital Markets analyst Robert LeBoyer has maintained an Outperform rating with a $15 target on (NTRB) — suggesting over 120% upside from this week's $6.75 range. That kind of gap between where a name sits and where an analyst says it should be valued is the sort of thing that gets attention when the potential catalysts start lining up. At the same time, the company recently received a Notice of Publication from the USPTO for commercial brand name trademarks for the AVERSA fen-tan-yl patch. 
That's not a lab milestone — that's a commercialization milestone. Building a commercial identity before the trial even begins shows a team thinking past approval and toward what comes after… And one of the biggest legacy overhangs on Nutriband’s share structure is now nearing a hard expiration date. The outstanding IPO warrants from 2021 — 910,904 warrants carrying a $6.43 exercise price — are set to expire on September 30, 2026, with no extension, no repricing, and no modification. The company has made the terms clear: holders either exercise before the deadline or those warrants disappear. That could mark an important cleanup event for the capital structure. After years of representing a known source of potential dilution, this warrant overhang is finally approaching its end — potentially leaving Nutriband with a cleaner share structure and one less lingering concern heading into one of the most consequential periods on the company’s calendar. 
For anyone watching (NTRB), the combination of trial progress, commercial branding, and structural cleanup happening simultaneously is hard to ignore. A Platform With More Than One Application
AVERSA fen-tan-yl is the lead program, but the story doesn't stop there. The company's broader development roadmap includes AVERSA Buprenorphine for chronic pain, AVERSA Methylphenidate for ADHD, and novel transdermal programs for Type 2 diabetes (4P Exenatide) and infertility (4P FSH) — all in pre-clinical stages. The AVERSA™ platform is designed to be compatible with virtually any transdermal patch… Each new application could address a separate market using the same core technology and the same 46-country patent portfolio. That's one of the things we find most compelling about (NTRB) — the lead product is the proving ground, but the technology itself has applications that go much further. The first exclusive international distribution agreement for AVERSA fen-tan-yl has already been signed — with Costa Rica's Innomedica CCB, adding the first non-U.S. territory to the potential market. The Costa Rican Ministry of Health has approved Nutriband's kinesiology tapes for import and sale through that partner, with Innomedica planning to begin AVERSA fen-tan-yl marketing in anticipation of approval. On the consumer side, the company's wholly owned subsidiary Active Intelligence has been building a presence in wellness, recovery, and performance products — including AI Tape, AI Energy Patches, and AI Sleep. The subsidiary met with buyers from Walmart, Walgreens, Amazon, and Cardinal Health at the ECRM conference earlier this year, and new product launches are already underway. These aren't theoretical retail conversations — the ECRM conference is one of the leading business development events connecting consumer brands with major distributors and pharmacy chains across North America. "Consumer demand for wellness, recovery, energy, and performance solutions continues to accelerate," said Gareth Sheridan, CEO of Nutriband Inc. (NASDAQ: NTRB). A pharmaceutical pipeline and a consumer wellness arm, running side by side on the same transdermal technology foundation… That's the kind of dual-channel structure that can create multiple ways to win. 9 Reasons Why We're Highlighting (NTRB) This Morning —Friday, September 25, 2026…
1. AVERSA™ Abuse-Deterrent Technology: The company's proprietary platform is protected by patents in 46 countries, designed to prevent the misuse, diversion, and accidental exposure of fen-tan-yl from transdermal patches — with no competing abuse-deterrent fen-tan-yl patch on the U.S. market today. 2. Single-Trial FDA Pathway: The 505(b)(2) route requires only one clinical trial to demonstrate that abusers prefer generic patches — with the trial expected to begin late Fall 2026. 3. Analyst Coverage at $15: Noble Capital Markets analyst Robert LeBoyer maintains an Outperform rating with a $15 target, suggesting over 120% upside from current levels. 4. Small-Float: With less than 6M shares listed as available to the public, (NTRB)’s small float could have the potential for big moves if demand begins to shift. 5. Warrant Expiration September 30: The 910,904 outstanding warrants expire September 30, 2026, with no extension and no modification — removing a longstanding structural overhang. 6. Commercial Brand Trademarks Filed: The USPTO has published trademark applications for the AVERSA fen-tan-yl commercial brand name, signaling active launch preparation ahead of the registration trial. 7. $1.2B Market With No Abuse-Deterrent Competition: The U.S. generic fen-tan-yl patch market is estimated at over $1.2B, and no currently available patch carries abuse-deterrent technology — giving AVERSA a potential first-mover position. 8. International Distribution Already Signed: The first exclusive agreement for AVERSA fen-tan-yl is in place with Costa Rica's Innomedica CCB, establishing a template for non-U.S. expansion ahead of approval. 9. Active Intelligence Consumer Pipeline: The company's wellness subsidiary is meeting with Walmart, Walgreens, Amazon, and Cardinal Health on new product lines including AI Tape, AI Energy Patches, and AI Sleep — building a second revenue channel alongside the pharmaceutical pipeline. Take A Look At (NTRB) While It’s Still Early…
The convergence of a registration trial, an analyst target well above current levels, a warrant overhang about to clear, and a first-mover position in a market with no abuse-deterrent competition — that's a combination we don't see very often… And with (NTRB) already showing the kind of momentum that comes when a name starts getting noticed, the window to pay attention feels like it's tightening. Take a close look at NTRB) while it’s still early. Also, keep an eye out for my next update, it could be here very soon. Sincerely, Alex Ramsay
Managing Editor,
Krypton Street |
No comments:
Post a Comment